NVSR, SLAT, ALRX, OOIL, ACCP, VM, AMFI, HTDS, SYMW, BEHL, BEDA Daily Market Movers Digest Midday Report for Tuesday, July 28th from OTCPicks.com
Our Stocks to Watch today include NavStar Technologies Inc. (OTC: NVSR), Superlattice Power Inc. (OTCBB: SLAT), AlphaRx Inc. (OTCBB: ALRX), OriginOil Inc. (OTCBB: OOIL), Access Pharmaceuticals Inc. (OTCBB: ACCP), Virgin Mobile USA Inc. (NYSE: VM), AMCORE Financial Inc. (Nasdaq: AMFI), Hard to Treat Diseases Inc. (OTC: HTDS), SymPowerco Corp. (OTC: SYMW), BioCentric Energy Holdings Inc. (OTC: BEHL) and Bederra Corp. (OTC: BEDA).
Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover’s Digest Newsletter and Email Stock Watch Alerts.
NAVSTAR TECHNOLOGIES INCORPORATED (OTC: NVSR)
"Up 30.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/NVSR.php
Company Profile: http://www.otcpicks.com/navstar-technologies/navstar-technologies.htm
NavStar is focused on the creation of GPS products and services that provide wireless tracking of vehicles, equipment, and other valuable and personal assets. The goal is to be a total solutions provider.
NVSR News:
July 28 - NavStar Field Testing a Great Success in
NavStar Reports Successful Field Test, as Conducted by Fixed Equipment S.A., and Government Purchase Order Is Weeks Away
NavStar Technologies, Inc. (OTC: NVSR), a multinational firm focused on developing and commercializing asset tracking and monitoring devices for vehicles and high value cargo with specific geographic focus in Latin America, today announced that the field trial in Ecuador has entered the final stages and will result in the execution of a Purchase Order for 4,033 units worth $732,000.
After several months and many hours of testing, the field trial with the public transportation system in
"With 25 units involved in the field trial we have stressed the system at all its critical points and it has proven itself extremely reliable and flexible and we are down to a few very minor software issues," said Roberto Manosalvas, General Manager, Fixed Equipment S.A. "NavStar's high quality device and technical support and our 'hands-on everyday' availability have been the deciding factor in winning this business."
"We are pleased that the field testing in
SUPERLATTICE POWER INCORPORATED (OTCBB: SLAT)
Detailed Quote: http://www.otcpicks.com/quotes/SLAT.php
Company Profile: http://www.otcpicks.com/superlattice-power.htm
Superlattice Power, Inc. was incorporated in
SLAT News:
July 28 - Superlattice Power Inc. to Establish a Fully Automatic Manufacturing Unit of Lithium Ion Batteries for Electric Vehicle Applications
Superlattice Power Inc. (OTCBB: SLAT), emerging leader in the development and marketing of next generation lithium-powered batteries worldwide, announces that the company is in the final stages of its negotiations with an Asian company for setting up a pilot scale production unit of Lithium Ion polymer batteries. The first production line will be located in
Superlattice Power Inc. is developing batteries for electric as well as hybrid vehicles. The new manufacturing plant will have an initial estimated rate of producing 36,000 unit cells per year equivalent to 450 electric vehicles. Once fully operational, Superlattice Power Inc. will achieve the targeted production capacity of approximately 100,000 cells annually.
Superlattice Power Inc. is a Lithium Ion battery company which has developed a cathode material for Lithium Ion batteries and thermal management system for EV battery packs, with a capacity nearly 1.5 times greater than the present commercially available cathode materials.
Superlattice Power Inc. is also engaged in the battery pack design activities in collaboration with EV Innovations Inc. and has a contractual agreement with EV Innovations Inc. to supply the Lithium Ion batteries for their Electric Vehicles.
ALPHARX INCORPORATED (OTCBB: ALRX)
"Up 5.56% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/ALRX.php
Company Profile: http://www.otcpicks.com/alpharx/alpharx.htm
AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.
ALRX News:
July 23 - AlphaRx Presents Positive Preclinical Data on Zysolin™ Inhalable Nanoparticles at Controlled Release Society Annual Meeting
AlphaRx, Inc. (OTCBB: ALRX) announced positive preclinical results which demonstrated that an inhaled tobramycin nanoparticle (Zysolin) formulation was a more effective treatment in animal models of acute Pseudomonas aeruginosa pneumonia when compared to inhaled and injected conventional tobramycin solutions. The data was presented recently in an oral podium session at the 36th Annual Meeting and Exposition of the Controlled Release Society in
"These are very encouraging results, as they suggest that Zysolin employed in this route of administration may be more effective, providing significant advantages over conventional drug formulations," stated Joseph Schwarz, Ph.D., Chief Scientist of AlphaRx. "We believe that building on this data, additional research will lead us toward the development of a drug that targets and eradicates intracellular pathogens, which to date, have proven to be very difficult to treat clinically."
The study results demonstrate that Zysolin is significantly efficacious in acute pneumonia animal models induced by gram negative pathogens including P. aeruginosa. In these lethality-based studies, Zysolin consistently increased survival rate to 50% over a Tobramycin treatment group, wherein all untreated animals died within 24 hours after infection. P. aeruginosa is one of the most common and lethal pathogens responsible for ventilator-associated pneumonia in intubated patients, being directly responsible for death rates approaching 40%. This data suggests that the nanoparticulate formulation of Zysolin may utilize a unique mechanism of action differentiating it from conventional formulations, enhancing antimicrobial activity against gram negative pathogens. Zysolin has the potential to be a first-in-class anti-infective nanomedicine.
The Controlled Release Society (CRS) is an international organization consisting of 3,000 members from more than fifty countries. Two-thirds of CRS membership are from the pharmaceutical industry and one-third consist of academic and government members. The CRS is the premier multidisciplinary society dedicated to the promotion of the science, technology, and innovative delivery of bio-actives for the benefit of the society.
ABOUT ZYSOLIN™
Zysolin is a Tobramycin compound, encapsulated in AlphaRx's Nano Drug Delivery Platform, intended for the adjunctive treatment of Gram-negative pneumonia in intubated and mechanically-ventilated patients. Zysolin improves the intracellular activity of Tobramycin — in layman's term, increasing the drug concentration of Tobramycin inside human macrophages, thus improving its antibacterial activity against intracellular Klebsiella, Pseudomondas aeruginosa and Staphylococcus bacterial strains in pneumonia patients. The active ingredient in Zysolin, Tobramycin, has a long-standing and proven clinical treatment record. Delivered by inhalation, using proprietary nanotechnology developed by AlphaRx, the company believes Zysolin will have an attractive safety, tolerability and efficacy profile when compared to injectible Tobramycin.
ORIGINOIL INCORPORATED (OTCBB: OOIL)
"Up 7.73% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/OOIL.php
Company Profile: http://www.otcpicks.com/originoil.htm
OriginOil, Inc. is developing a breakthrough technology that will transform algae, the most promising source of renewable oil, into a true competitor to petroleum. Much of the world's oil and gas is made up of ancient algae deposits. Today, our technology will produce "new oil" from algae, through a cost-effective, high-speed manufacturing process. This endless supply of new oil can be used for many products, such as diesel, gasoline, jet fuel, plastics and solvents, without the global warming effects of petroleum. Other oil-producing feedstock, such as corn and sugarcane, often destroy vital farmlands and rainforests, disrupt global food supplies and create new environmental problems. Our unique technology, based on algae, is targeted at fundamentally changing our source of oil without disrupting the environment or food supplies.
OOIL News:
July 27 - OriginOil Announces Breakthrough Process for Live Algae Oil Extraction
Algae ‘milking’ promises new efficiencies as part of a combined production cycle
OriginOil, Inc. (OTCBB: OOIL), the developer of a breakthrough technology to transform algae, the most promising source of renewable oil, into a true competitor to petroleum, announced that it has succeeded in extracting algae oil on a continuous basis without cell sacrifice. This new ‘milking’ process will join the company’s Cascading Production™ technique to create a combined cycle promising new efficiencies.
Live Extraction™, or milking, is inherently efficient because it achieves continuous production of algae oil without destroying the algae cell. Therefore a single algae cell can produce more oil during its lifetime using lower amounts of energy. Unlike other approaches to live extraction, OriginOil’s process does not employ expensive consumables such as reverse osmosis membranes; furthermore, it is not limited to oil-bearing algae strains, such as Botryococcus braunii, that are known to excrete algae oil naturally.
Algae typically protect their oil behind a tough cell wall. The challenge of live extraction is to harvest the oil without causing permanent damage to the cell. This goal has been achieved in the laboratory at bench scale and is now being scaled up to OriginOil’s intermediate 200-gallon tank size. A diagram illustrates the process at www.originoil.com/technology/live-extraction.html.
The company recently filed for patent protection of the new Live Extraction process, its ninth patent application, entitled “Procedure for Extraction of Lipids from Algae without Cell Sacrifice.” “Live Extraction works by stimulating the algae cells through specific electrical modulations,” Riggs Eckelberry, OriginOil’s CEO, said. “The challenge is how to keep the cells alive while continuously extracting the oil, and we have achieved this.”
“We are pleased with the results we are getting from conventional harvesting,” said Vikram Pattarkine, PhD, OriginOil’s CTO. “We expect the new Live Extraction process to coexist with our daily ‘destructive’ process to create an even more efficient combined cycle.”
Aside from any production gains, combining the two processes is desirable because algae cultures must be refreshed regularly to remove waste toxins. Cascading Production supports Live Extraction by removing a percentage of the culture every day, refreshing the environment and giving the algae culture space to grow.
Following Exxon Mobil’s recent announcement of a $600 million investment in San Diego- based Synthetic Genomics, Paul Reep, senior technical adviser and one of the inventors, noted: “Live lipid extraction is especially beneficial when used with algae that have been genetically engineered for faster growth rate or higher lipid yields. By integrating Live Extraction into our process, we are providing a technology platform for companies like Synthetic Genomics that are experimenting with genetic improvements.”
OriginOil Inc.'s Technology Update Prompts Updated Rating by BeaconEquity Research
OriginOil Inc. (OTCBB: OOIL) receives updated Speculative Buy from Beacon Analyst Victor Sula, Ph.D., fueled by the Company’s recent patent applications for its “milking” process to extract algae oil, a patent filing for its Dynamic Control System, and its application or a Patent Cooperation Treaty for low-energy, high-efficiency algae production.
The full report is available at http://www.beaconequity.com.
Anyone interested in receiving alerts regarding OOIL research should e-mail members@beaconequity.com with “OOIL” in the subject line.
In the report, the analyst writes:
“The renewable energy sector has already recognized the potential of algae as a feedstock to replace soybean, rapeseed and corn in biofuel production. … Because of these advantages, we expect larger-scale production of algae and/or algae-biomass products over the next five years.
“Robust clean energy demand, OOIL’s progress in advancing its proprietary algae biofuel technologies and the significant future revenue potential associated with licensing this technology to biofuel manufacturers and refiners are reasons we continue to rate OOIL a Speculative Buy.”
Other companies in the research services industry include: Nanoforce Inc. (OTC: NNFC), PetroSun Inc. (OTC: PSUD), Green Star Products Inc. (OTC: GSPI) and Valcent Products Inc. (OTCBB: VCTPF).
ACCESS PHARMACEUTICALS INCORPORATED (OTCBB: ACCP)
"Up 9.09% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/ACCP.php
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac™, currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard™ for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin™-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix®, a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers.
ACCP News:
July 27 - Access Pharmaceuticals Announces Commercial Launch of MuGard™ in
Early Market Assessment Studies Suggest Larger Market Potential
Access Pharmaceuticals, Inc. (OTCBB: ACCP) announced that its European partner, SpePharm, has commenced commercial launch of MuGard in
Central to the MuGard commercial launch strategy is a coordinated effort to seek reimbursement from governmental agencies, placement in pharmacy formularies and an aggressive seeding strategy in leading cancer treatment centers and with leading clinicians. Aggressive sampling and education of patients and clinicians on early prophylactic use is proving important in reducing incidence, severity and duration of oral mucositis.
"The early feedback includes a high rate of enthusiasm and intention to continue use by practicing clinicians and patients, who have used MuGard," stated Jeffrey B. Davis, Access' President & CEO. "We believe this enhanced awareness of the benefits associated with use of MuGard as a preventative treatment is likely to result in solid marketing traction and market penetration in
MuGard is a novel, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 40% of all patients receiving chemotherapy and/or radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis, expanding to include all patients undergoing chemotherapy and radiotherapy, is estimated to be in excess of $5 billion world-wide.
MuGard forms a protective coating over the oral mucosa when swirled gently around the mouth. In a comparison of cancer patients receiving standard mucositis care with those patients receiving MuGard, the incidence and severity of mucositis was significantly lower in the MuGard treated group using a validated scale for the assessment of oral mucositis.
VIRGIN MOBILE
"Up 23.04% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/VM.php
Virgin Mobile USA, Inc., through its operating company Virgin Mobile
VM News:
July 28 - Sprint Nextel To Acquire Virgin Mobile
Strengthens Company’s Prepaid Position in Wireless Market with Iconic Consumer Brand; Public Shareholders to Receive $5.50 per Share
Sprint Nextel Corporation (NYSE: S) and Virgin Mobile USA, Inc. (NYSE: VM) announced that their boards of directors have approved a definitive agreement for Sprint to acquire Virgin Mobile USA for a total equity value of approximately $483 million, which includes the value of Sprint’s current 13.1% fully diluted ownership interest in Virgin Mobile USA. In addition, at closing Sprint will retire all of Virgin Mobile USA’s outstanding debt, which is $248 million net of cash and cash equivalents as of March 31, 2009, but is expected to be no more than $205 million net of cash and cash equivalents on Sept. 30, 2009.
This acquisition will strengthen Sprint’s position in the growing prepaid segment by bringing together under one umbrella the iconic Virgin Mobile brand with Sprint’s successful Boost Mobile business. These complementary prepaid brands, each with a distinctive offer, style and appeal to different customer demographics, will continue to serve existing and prospective customers following the completion of the transaction.
Following the closing of the transaction, Sprint’s prepaid business will be led by Dan Schulman, current Virgin Mobile USA chief executive officer, who will report directly to Dan Hesse, Sprint Nextel president and chief executive officer. Bringing exceptional telecom leadership credentials to Sprint, Schulman will be responsible for the business strategy and growth of the prepaid segment. Matt Carter will continue to lead Boost Mobile and will report to Schulman.
“The acquisition of Virgin Mobile
“I have known Dan Schulman for many years, and I feel very fortunate that a leader with Dan’s talents is joining Sprint to take us to even greater heights in prepaid,” added
“Virgin Mobile
Transaction Benefits
A) Strengthens Sprint’s position in the fast growing prepaid segment.
B) Enhances cross selling of full suite of Sprint products and services across a larger target audience.
C) Free cash flow accretive for Sprint before synergies.
D) Synergies to be derived from general and administrative reductions, operational efficiencies, and streamlined distribution.
E) Sprint gains deeper managerial talent with additional expertise in the prepaid segment.
Terms of the Transaction
Under the terms of the agreement, Virgin Mobile USA stockholders will receive shares of common stock of Sprint based on the exchange ratios described in more detail below, and cash in lieu of fractional shares.
Virgin Mobile
Each public stockholder, holding in aggregate approximately 39.7 million shares on a fully diluted basis or 43.3% ownership, will receive Sprint shares having a 10-day average closing price equivalent to $5.50 per Virgin Mobile
1) The exchange ratio for public stockholders will be based on Sprint’s 10-day average closing share price ending two trading days prior to closing.
2) The exchange ratio will be subject to a collar such that in no event will the exchange ratio be lower than 1.0630 or higher than 1.3668.
The Virgin Group:
* The exchange ratio for the Virgin Group will in all circumstances be equal to 93.09% of the exchange ratio for the public stockholders equating generally to $5.12 per Virgin Mobile USA share for common stock owned by the Virgin Group (including shares into which preferred stock held by it is convertible.)
* Preferred shares owned by Virgin Group will be converted into common stock based on the Virgin Group exchange ratio at a conversion price of $8.50.
* Virgin Group owns approximately 26.0 million shares on a fully diluted basis or 28.3% ownership, of Virgin Mobile USA.
SK Telecom:
* The exchange ratio for the SK Telecom will in all circumstances be equal to 89.84% of the exchange ratio for the public stockholders, equating generally to $4.94 per Virgin Mobile USA share for common stock owned by SK Telecom (including shares into which preferred stock held by it is convertible.)
* Preferred shares owned by SK Telecom will be converted into common stock based on the SK Telecom exchange ratio at a conversion price of $8.50.
* SK Telecom owns approximately 14.0 million shares on a fully diluted basis or 15.3% ownership, of Virgin Mobile USA.
Based on the terms of the agreement, Sprint currently expects to issue between 81.4 million and 104.7 million shares of its common stock in exchange for all Virgin Mobile USA common stock, excluding Sprint’s 13.1% stake, and all Virgin Mobile USA preferred stock.
Following the closing of the transaction, Virgin Mobile USA will continue to license the Virgin Mobile USA brand from the Virgin Group under the terms of an amended and restated Trademark License Agreement. Sprint will pay $12.7 million for the initial term, which will continue through the end of 2021. The agreement contains several renewal provisions that will allow Virgin Mobile USA to extend the term until 2047.
Sprint will pay Virgin Group approximately $50 million at closing as payment in full for net operating losses available to be utilized by Virgin Mobile USA in the future under the Tax Receivable Agreement.
All of Virgin Mobile USA’s outstanding debt will be retired at the closing of the transaction including amounts due under the Senior Secured Credit Facility and the Related Party Subordinated Secured Revolving Credit Agreements.
The payments at the closing of the transaction for the Trademark License Agreement, the Tax Receivable Agreement and Virgin Mobile USA’s subordinated debt will be made either in cash or stock, at Sprint’s option.
The transaction is subject to various closing conditions, including the approval of the transaction agreement by Virgin Mobile USA’s stockholders, the receipt of applicable regulatory approvals, and other customary closing conditions. The Virgin Group and SK Telecom have agreed to vote a portion of the Virgin Mobile USA voting shares owned by them that, when aggregated with the voting shares owned by Sprint, comprise approximately 40% of the outstanding voting power. The transaction is expected to be completed in the fourth quarter of 2009 or in early 2010.
Sprint was advised by Wells Fargo Securities and King & Spalding. Deutsche Bank Securities Inc., Colonnade Advisors LLC and Foros Advisors LLC are acting as financial advisors to an independent special committee of the Board of Directors of Virgin Mobile and Deutsche Bank Securities Inc. also has provided a fairness opinion to the committee. Virgin Mobile USA was also advised by Simpson Thacher & Bartlett LLP.
ABOUT SPRINT NEXTEL
Sprint Nextel offers a comprehensive range of wireless and wireline communications services bringing the freedom of mobility to consumers, businesses and government users. Sprint Nextel is widely recognized for developing, engineering and deploying innovative technologies, including two wireless networks serving more than 49 million customers at the end of the fourth quarter 2008; industry-leading mobile data services; instant national and international push-to-talk capabilities; and a global Tier 1 Internet backbone.
AMCORE FINANCIAL INCORPORATED (NASDAQ: AMFI)
"Up 29.45% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/AMFI.php
AMCORE Financial, Inc. is headquartered in Northern Illinois and has banking assets of $4.9 billion with 73 locations in Illinois and Wisconsin. AMCORE provides a full range of consumer and commercial banking services, a variety of mortgage lending products and wealth management services including trust, brokerage, private banking, financial planning, investment management, insurance and comprehensive retirement plan services. AMCORE common stock is listed on The NASDAQ Stock Market under the symbol "AMFI."
AMFI News:
July 28 - AMCORE Financial, Inc. Reports 2nd Quarter Results
Delinquencies, Charge-Offs Decrease; Loan Loss Provision Lower by Nearly 75%
AMCORE Financial, Inc. (Nasdaq: AMFI) announced financial results for the second quarter 2009.
AMCORE reported a net loss of ($10.7) million for second quarter 2009, compared to a net loss of ($30.4) million in the previous quarter and a net loss of ($20.2) million in the prior-year period. Loss per diluted share was ($0.47) for second quarter 2009, compared to a loss of ($1.34) in the previous quarter and a loss of ($0.89) per diluted share in second quarter 2008.
During the second quarter, AMCORE experienced a significant decrease in the rate of growth in non-performing loans, which was at its lowest level since third quarter 2007. In addition, charge-offs were at the lowest level since a year ago. As a result, AMCORE's reported loss for the quarter was two-thirds less than the previous quarter and approximately 50 percent less than a year ago.
"Our results show the benefits from the aggressive actions taken early in this recession addressing our credit issues and improving our overall operating efficiencies," said William R. McManaman, Chairman and CEO of AMCORE. "The improvements in key credit quality indicators during the quarter are the result of our hard work over the past 18 months to rebuild our credit management practices, strengthen our lending function and reduce our concentration in construction and development loans. Our corporate restructuring and other cost saving measures resulted in a 17 percent decrease in core operating costs, excluding FDIC insurance costs, compared to a year ago.
"Going forward, we continue to work to further strengthen and improve the Bank's financial condition and operations. We believe the regulators have seen the considerable progress we have made and we continue to work toward achieving the directives in the recent consent order and regulatory agreement. We are adequately capitalized at both the Bank and consolidated level. Recognizing that the economy remains challenging for banks in general and for our customers, we are committed to further improving our Company while maintaining our focus on delivering service excellence to our customers."
HARD TO TREAT DISEASES INCORPORATED (OTC: HTDS)
"Up 272.73% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/HTDS.php
In June 2003, International Foam Solutions, Inc. changed its name to Hard to Treat Diseases, Inc. in connection with the completion of a share exchange agreement with Hard to Treat Diseases and T-19, Inc. Hard to Treat Diseases, Inc. holds the international marketing rights, except South Korea, to Tubercin, a patented immunostimulant developed for combating cancer and rheumatoid arthritis under medical patent. Tubercin promotes good health by enhancing the immune system. The nasal spray would be distributed through major holistic retailers and providers worldwide.
HTDS News:
July 28 - Hard to Treat Diseases To Re-Release European TV Segment In North America For Potential Treatment Of MS
Hard to Treat Diseases, Inc. (OTC: HTDS) Slavica Bio Chem Division (Slavica) intends to re-release a TV feature on the work of the medical team in the area of potential treatment of MS. The TV feature was aired in Europe only, several years ago.
Dr. Sanja Pekovic, Chief Project Scientist, Chief Strategy Officer explains: "A few years ago Serbian government TV did a feature about our work, and it took a great public attention. It was about Multiple sclerosis, current therapies, there were also some patients, and our whole team. All of us were talking about our work, our results, our lab was also presented. Also, there were some short movies about MS. It was very good and they repeated it several times on TV." Currently the company is in the process of obtaining translations and writing to the Director of RTS (TV) and intends to post the interview on its corporate web sites www.slavicabiotech.com and www.htdsmedical.com. The company intends to make use of other media ie CD/DVD and similar to distribute the content to other medical professionals, research organizations, and companies in the medical industry to shed additional spotlight on the work of the Slavica Bio Tech team.
In other company news, within the next few weeks Slavica Bio Tech division intends to conduct a web cast only to address the work of Slavica. Dr.Sanja Pekovic, added: "Considering the potential, the exposure, and the spotlight this interview may bring to the company we are grateful and it is our pleasure, to have Professor Rakic accept our invitation to be Slavica's spokesperson for the web cast. He is our Chief scientist and Ribavirin was his idea at the start. Professor Rakic is a well known and highly regarded and respected scientist. He is also the Vice-President of the Serbian Academy of Sciences and Arts in charge for natural sciences."
Company followers are advised that a similar and a second web cast is being planned to feature only the Mellow Hope (HTDS China Subsidiary Vaccine Division). This second webcast will be chaired by the HTDS CEO, Mr. Terry Yuan.
Dr Pekovic concluded: "We are eager to get the message out to the industry on the work that our team is doing at Slavica. By that we mean not only to our shareholders but to the medical industry as well. We believe that our work is invaluable, that we have made some significant strides, which simply cannot be ignored and we believe that the market is just starting to take notice of our potential. To that end we have hired a liaison contact person, Dr. Ivana Gadjanski. Ivana comes highly qualified to us. She is a PhD. She has recently returned from Germany where she finished her PhD studies and got her PhD diploma, and now is a part of our team. Also, she is an assistant professor at the State University Novi Pazar, she speaks: English -professionally, CAE certificate, grades A, German - upper intermediate level, French - basics and is an enthusiastic young scientist with a lot of fresh and original ideas.
In our team she is responsible for introducing stem cell therapy in our models of EAE/MS and traumatic brain injury. Her duties will also include sending regular updates of our work to our North American office, the head office in China, and having our North American office and our advisors disseminate timely updates to the HTDS followers, shareholders and the medical professionals."
The company intends to provide many updates on the work and HTDS activities on a timely basis.
SYMPOWERCO CORPORATION (OTC: SYMW)
"Up 12.50% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/SYMW.php
SymPowerco Corporation develops advanced fuel cell and power delivery systems for the rapidly growing personal transportation and portable power system markets being created by today's energy and environmental challenges.
SYMW News:
July 28 - SymPowerco Acquires Majority Stake in HMSI, HHHI
SymPowerco Corporation (OTC: SYMW) CEO John Davenport announced that the company has closed an agreement with Mr. Steven Humphries and the shareholders of Hoss Motor Sports, Inc. ("HMSI") and Highline Hydrogen Hybrids, Inc ("HHHI") by which the company will acquire majority interests in both HMSI and HHHI. The closing of the agreement completes the terms of the Letters of Intent previously announced on May 11, 2009 (HMSI) and June 30, 2009 (HHHI).
Under the terms of the all-stock agreement, SymPowerco will acquire 70% ownership of both HMSI and HHHI by issuing to Mr. Humphries common shares representing 51% of the post-issuance outstanding shares of SymPowerco, to the shareholders of HMSI and HHHI shares representing 27.5% of the post-issuance outstanding shares of SymPowerco and to related parties shares representing 12% of the post-issuance outstanding shares of SymPowerco.
Hoss Motor Sports Inc. has designed several types of Off Road Utility Vehicles including vehicles designed specifically for Search and Rescue, Construction Sites and for Sport Utility and Off Road Enthusiast markets. Under the SymPowerco umbrella, HMSI will manufacture its advanced vehicles at HMSI's new facility in Dumas, Arkansas.
HHHI has developed a unique supplemental hydrogen fuel system for Internal Combustion Engines that reduces dangerous emissions, enhances fuel efficiency by as much as 25% and increases horsepower by an average of 10%. HHHI plans to release a version of its supplemental fuel system for use on Over-The-Road commercial vehicles. The HHHI products will also be produced in the company's new facility in Dumas, Arizona.
BIOCENTRIC ENERGY HOLDINGS INCORPORATED (OTC: BEHL)
"Up 32.08% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/BEHL.php
BioCentric Energy, Inc. is dedicated to the development of new technologies as well as acquiring and fostering companies with innovative technologies designed to provide unique and effective green energy solutions for the 21st century. Along with the cultivation of important relationships and partnerships with synergistic entities, BioCentric Energy has devoted substantial time and effort in research and development in order to bring a range of innovative green alternatives to the marketplace.
BEHL News:
July 28 - BioCentric Energy Holdings Production Update
BioCentric Energy Holdings, Inc. (OTC: BEHL) announced the company's following photobioreactor production updates.
BioCentric President Dennis Fisher today announced the following updates for the production and ALGAE harvesting for the company's onsite closed loop photobioreactor system. "The 1800 square foot bioreactor is now operating in a totally 'Environmentally Green' process as the system is now completely flooded with reclaimed water. The ALGAE from this initial process is expected to be harvested early next week approximately five days ahead of the original estimated schedule, and based on the current flow rate the ALGAE is expected to be harvested twice daily. The current strain being produced is a Scenedesmus dimorphus ALGAE culture type that when harvested is typically used for producing clean burning Jet Fuel and Gasoline."
Mr. Fisher further stated, "BioCentric has had the remarkable opportunity to be a pilot developer in this huge upcoming industry, and since Exxon's announcement last week of the company's allocated $600M ALGAE Research & Development program, we are more confident than ever that our closed loop system technology will be in demand worldwide. As a result of the increased number of inquiries regarding ALGAE production and our closed loop system we are today starting assembly of the second closed loop system at our San Juan Capistrano, California Corporate facility and most of the materials are now onsite to commence production. This system will be producing a Spirulina ALGAE strain which when harvested is primarily developed for use in Nutritional supplements."
Company COO Dennis Shen returns this week from Asia where he was able to negotiate several milestones relating to significant cost savings in the manufacturing of patent pending components for the closed loop photobioreactor system enabling the company to be one of the first manufacturers of commercial size closed loop photobioreactor systems in such a cost effective manner that the NAA (National ALAGE Association) President Barry Cohen described BioCentrics all Green cost effective production system as the Wal-Mart of ALGAE production equipment.
Mr. Shen's trip enabled the company to enter negotiations for a Teaming Agreement with Zhenxing Co, Ltd, a Chinese corporation with offices at Lanhe Town, Panyu District, Guangzhou, China. The purpose of the teaming arrangement is where the parties will jointly develop the Algae Biofuel project in China and leverage the resources in China to design and manufacture certain components for Biocentric's global operations.
BEDERRA CORPORATION (OTC: BEDA)
"Up 400.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/BEDA.php
Bederra Corporation, through its wholly owned subsidiaries Diagnos, Inc. and Lumar Imaging, Inc., provides multiple modality diagnostic medical imaging services to the greater Houston area and the world famous Texas Medical Center. The Company's business strategy is to continue to expand its current operations and seek out additional acquisitions that will complement its core offerings.
BEDA News:
July 14 - Bederra Corporation Signs Letter of Intent to Acquire Neogenex Medical Technologies, Inc.
Bederra Corporation (OTC: BEDA), a medical imaging and diagnostic Company, has signed a Letter of Intent to acquire Neogenex Medical Technologies, a Houston, TX based Technology, Development and Marketing company that focuses on Pain Therapies for Arthritis, Soft tissue and Joint applications.
Neogenex Medical Technologies, Inc. has rights to patents and technology to produce and market a low level laser device cleared by the FDA to treat arthritis pain and carpal tunnel syndrome. The company currently markets these FDA approved devices to medical professionals, Fitness Clubs and Corporate Wellness Facilities. More than 3500 medical professionals, therapists and trainers are currently using these devices as treatment options.
"The current market for these products and treatments is well over $10-15 Billion as more than 80 million people can utilize these therapies. Neogenex has already established itself in this market and would make a great addition to Bederra's growing line of products and services," stated Graham Williams, CEO of Bederra.
OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it.
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.
Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov/ and FINRA at http://www.finra.org.
Disclosure: OTCPicks.com has been compensated eight thousand dollars by a third party (Mickey Reno) for NVSR advertising and promotional services. OTCPicks.com has been previously compensated two thousand five hundred dollars by a third party (Blue Wave Advisors) for SLAT advertising and promotional services. OTCPicks.com has been recently compensated two thousand five hundred dollars by a third party (Blue Wave Advisors) for the current SLAT advertising and promotional campaign. OTCPicks.com has been compensated seven thousand five hundred dollars by a third party (Blue Wave Advisors) for ALRX advertising and promotional services. OTCPicks.com previously compensated three thousand dollars by a third party (Blue Wave Advisors) for a one-week OOIL advertising and promotional program. In this OOIL promotional campaign OTCPicks is being compensated three thousand dollars by a third party (Blue Wave Advisors). OTCPicks.com has been compensated three thousand five hundred dollars by a third party (Longview Communications Corp.) for ACCP advertising and promotional services. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. OTCPicks.com is a website partially owned by BlueWave Advisors, LLC, a financial public relations firm. BlueWave Advisors, LLC, its principal and/or its affiliates will hold positions in the company profiled and may buy or sell securities at any time without notice.
